CEPROTIN
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $13,250 | 1 | 1 |
| 2023 | $27,828 | 11 | 2 |
| 2022 | $27,590 | 12 | 5 |
| 2017 | $7,051 | 45 | 6 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $40,219 | 9 | 53.1% |
| Travel and Lodging | $22,826 | 23 | 30.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,591 | 1 | 7.4% |
| Unspecified | $4,995 | 2 | 6.6% |
| Food and Beverage | $1,824 | 33 | 2.4% |
| Education | $263.55 | 1 | 0.3% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT | Takeda Pharmaceuticals U.S.A., Inc. | $4,995 | 1 |
Top Doctors Receiving Payments for CEPROTIN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Pediatric Hematology-Oncology | Memphis, TN | $39,988 | 13 |
| , M.D | Pediatric Hematology-Oncology | Los Angeles, CA | $19,677 | 16 |
| , MD | Pediatric Hematology-Oncology | Aurora, CO | $8,370 | 3 |
| , M.D | Pediatrics | San Diego, CA | $1,913 | 1 |
| , MD | Pediatrics | Little Rock, AR | $1,688 | 1 |
| , MD | Pediatric Hematology-Oncology | Atlanta, GA | $1,188 | 9 |
| , MD | Hematology | New York, NY | $1,165 | 9 |
| , M.D | Hematology & Oncology | Seattle, WA | $1,163 | 9 |
| , M.D | Hematology & Oncology | West Roxbury, MA | $305.14 | 7 |
| , D.O., MPH | Dermatology | Fort Lauderdale, FL | $263.55 | 1 |
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $75,719
- Total Doctors 10
- Transactions 69
About CEPROTIN
CEPROTIN is a biological associated with $75,719 in payments to 10 healthcare providers, recorded across 69 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Pharmaceuticals U.S.A., Inc..
Payment data is available from 2017 to 2024. In 2024, $13,250 was paid across 1 transactions to 1 doctors.
The most common payment nature for CEPROTIN is "Consulting Fee" ($40,219, 53.1% of total).
CEPROTIN is associated with 1 research study, including "A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT" ($4,995).